Dosing Recommendations for Memantine and Donepezil
For donepezil, start at 5 mg once daily in the evening and increase to 10 mg after 4-6 weeks; for memantine, start at 5 mg once daily and titrate weekly by 5 mg in divided doses to reach the target of 20 mg daily (10 mg twice daily). 1, 2
Donepezil Dosing Algorithm
Mild to Moderate Alzheimer's Disease
- Starting dose: 5 mg once daily in the evening, just prior to retiring
- Titration: After 4-6 weeks on 5 mg, increase to 10 mg once daily
- Maximum dose: 10 mg/day 1
Moderate to Severe Alzheimer's Disease
- Starting dose: 5 mg once daily in the evening
- First titration: After 4-6 weeks, increase to 10 mg once daily
- Second titration: After at least 3 months on 10 mg, may increase to 23 mg once daily
- Maximum dose: 23 mg/day 1
Important administration details: Take in the evening before bed, with or without food. The 23 mg tablet must not be split, crushed, or chewed 1.
Memantine Dosing Algorithm
Moderate to Severe Alzheimer's Disease (Monotherapy or with Donepezil)
- Week 1: 5 mg once daily
- Week 2: 5 mg twice daily (10 mg/day total)
- Week 3: 10 mg in morning, 5 mg in evening (15 mg/day total)
- Week 4 onward: 10 mg twice daily (20 mg/day target dose) 2
The FDA label clearly demonstrates this weekly titration schedule, which minimizes adverse effects while reaching therapeutic levels 2.
Combination Therapy Considerations
When combining donepezil and memantine for moderate to severe AD, both drugs should be at their target doses: donepezil 10 mg daily and memantine 20 mg daily (10 mg twice daily). This combination demonstrates superior efficacy compared to either agent alone 2, 3.
The evidence strongly supports combination therapy:
- In patients already stabilized on donepezil 10 mg for at least 6 months, adding memantine produced statistically significant improvements in cognition (SIB), activities of daily living (ADCS-ADL), global function (CIBIC-Plus), and behavioral symptoms 3
- The combination increased 5-year survival probability by 6.4% compared to no treatment, with a significant beneficial drug-drug interaction effect 4
- Recent real-world data from 2025 shows that low-dose donepezil (5 mg) combined with memantine produces similar cognitive and functional outcomes as high-dose donepezil (10 mg) with memantine, but with significantly fewer adverse events (11.11% vs 27.87%) and better quality of life 5
Clinical Practice Nuances
Adverse Event Management
Gastrointestinal side effects (nausea, vomiting, diarrhea) are dose-dependent with donepezil 6, 1. The 10 mg dose causes more GI effects than 5 mg, and 23 mg causes markedly more than 10 mg (11.8% vs 3% nausea incidence) 1. The slow titration schedule helps minimize these effects.
For memantine, withdrawal rates due to adverse events are relatively low (9-12% vs 7-13% for placebo), with nausea, dizziness, diarrhea, and agitation being most common 7, 2.
Disease Stage-Specific Approach
- Mild to moderate AD: Donepezil 5-10 mg is the primary evidence-based choice 6, 1
- Moderate to severe AD: Both donepezil (10 mg) and memantine (20 mg) are indicated, with strong evidence favoring combination therapy 7, 2, 3
Common Pitfalls to Avoid
- Don't rush titration: The 4-6 week waiting period before increasing donepezil from 5 to 10 mg is critical for tolerability 1
- Don't use 23 mg donepezil as first-line: This higher dose requires at least 3 months on 10 mg and has significantly higher adverse event rates without proportional benefit 1, 5
- Don't forget memantine's weekly titration: Jumping directly to 20 mg increases adverse events; the weekly 5 mg increments are essential 2
- Don't overlook cardiovascular monitoring: Donepezil can cause bradycardia and heart block due to vagotonic effects 1
Fixed-Dose Combination Option
A fixed-dose combination capsule containing memantine extended-release 28 mg and donepezil 10 mg is available and bioequivalent to co-administered individual drugs, which may improve adherence and reduce caregiver burden 8, 9.